Physician profile
Jennifer E Horn
NPI 1649267204
$3,958.25
in general payments reported to CMS, 2019-2025
36 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $80.63 · 2021: $142 · 2022: $430 · 2023: $659 · 2024: $1,225 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,000.93 | 2021-2025 | |
| Novo Nordisk INC | $461.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $379.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $311.09 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $308.82 | 2022-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $145.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $141.63 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $119.80 | 2023-2025 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $114.64 | 2023-2024 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.33 | 2019-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $84.72 | 2022-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $84.00 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.33 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $60.20 | 2023-2024 | Auvelity, Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.98 | 2019-2024 | Xifaxan, Trulance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $49.00 | 2024 | |
| Amarin Pharma, INC. | $44.81 | 2019 | |
| Amgen INC. | $43.88 | 2019-2024 | Otezla, Repatha |
| Corcept Therapeutics | $40.11 | 2025 | Korlym |
| Sanofi Pasteur INC. | $34.27 | 2020-2024 | |
| Becton, Dickinson and Company | $33.74 | 2024 | Bd Max System, Bd Max Instrument |
| Novartis Pharmaceuticals Corporation | $29.00 | 2022 | |
| Glaxosmithkline, LLC. | $27.40 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $24.18 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $22.37 | 2019 | |
| Inspire Medical Systems, INC. | $18.72 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $18.46 | 2022 | |
| Blueprint Medicines Corporation | $18.20 | 2024 | Ayvakit |
| Dexcom, INC. | $15.94 | 2023 | Dexcom G6 Transmitter |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.74 | 2025 | |
| Jazz Pharmaceuticals INC. | $15.22 | 2020 | |
| Eisai INC. | $14.74 | 2024 | |
| Insulet Corporation | $14.66 | 2024 | Omnipod |
| Merck Sharp & Dohme LLC | $14.44 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.33 | 2019 | |
| Lundbeck LLC | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.